Giving Immune Checkpoint Inhibitors Within 90 Days of Radiation Appears Safe
Rates of adverse events were generally similar between patients who did and did not receive radiation.
Head and Neck Cancer
SD-101 Plus Pembrolizumab Elicits Responses in Head and Neck Cancer
Responses were seen in injected and non-injected lesions.
Oropharyngeal Cancer Incidence, Mortality Up Among U.S. Men
The incidence of oropharyngeal cancer in men increased 2.7% per year.
Incidence of Oropharyngeal Cancer Projected to Rise in U.S. Men
Under a status quo scenario based on current levels of HPV vaccination, 792,000 OPC cases in men would be prevented by the year 2100.
Tislelizumab Plus Chemotherapy as First-Line Tx Improves PFS for Nasopharyngeal Cancer
The phase 3 RATIONALE 309 trial was designed to evaluate the efficacy and safety of tislelizumab plus chemotherapy in adults with recurrent or metastatic nasopharyngeal cancer.
New Approach Promising for Diagnosis of HPV-Linked HNSCC
A blood test used to detect circulating tumor HPV DNA may shorten the time to diagnosis of HPV-associated head and neck squamous cell carcinoma.
Surgery Plus Radiotherapy Yields ‘Outstanding’ PFS in HPV+ Oropharyngeal Cancer
The 2-year progression-free survival rate exceeded 90% for all treatment arms.
Abiraterone Plus LHRH Is Active and Safe for Androgen Receptor-Positive Salivary Gland Tumors
The ORR and survival observed with abiraterone were found to be clinically meaningful for a second-line chemotherapy-free approach in AR-positive patients with salivary gland carcinoma.
Survey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...